Top Markets
Coin of the day
Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL
Kedudukan dalam Saham #12088
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Harga Saham
$2.34
Disegerakkan terakhir: 2026-08-28
Modal Pasaran
$621.44M
Perubahan (1 hari)
-1.06%
Perubahan (1 tahun)
55.67%
Negara
GB
Perdagangan Autolus Therapeutics plc (AUTL)

Kategori

Sejarah harga saham bagi Autolus Therapeutics plc (AUTL)
Harga penutupan tertinggi: $2.28 pada 2026-08-01

Harga penutupan terendah: $26.43 pada 2018-06-01
Sejarah harga saham Autolus Therapeutics plc dari 2018 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2026 (TTM) -2.43%
2025 -37.78%
2024 -48.76%
2023 131.99%
2022 -61.84%
2021 -37.82%
2020 -34.48%
2019 -57.61%
2018 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$542.09 38.63%
US
$1.03K 44.13%
NL
$121.36 -12.82%
AU
$138.18 473.58%
US
$759.27 7.20%
CH